A Phase III trial of Rhythm Pharmaceuticals’ Imcivree (setmelanotide) failed to meet its primary endpoints in four rare, ...

Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. When Sarepta Therapeutics revealed this month that a ...

COPENHAGEN (Reuters) -Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said ...

A new study finds just 6% of clinical trials used to approve new drugs in the U.S. reflect the country's racial and ethnic makeup, with an increasing trend of trials underrepresenting Black and ...

Novo Nordisk encountered a significant disappointment this week when the company announced that late-stage trials of Rybelsus failed to demonstrate effectiveness in slowing cognitive decline among ...

Findings showed the change from baseline in CDR-SB score was not significantly improved with semaglutide compared with placebo. Oral semaglutide did not significantly reduce disease progression in ...

Shares of Novo Nordisk fell sharply on Monday after the company announced that a high-profile trial testing whether its oral semaglutide medicine could slow the progression of Alzheimer’s disease had ...

(CNN) — An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, Novo Nordisk ...

Two of the most closely watched Alzheimer clinical trials of the decade have delivered a sobering verdict: GLP-1 drugs that revolutionized diabetes and weight loss did not slow the disease’s ...

A retrospective analysis found that strategic decisions and recruitment challenges were leading contributors to head and neck squamous cell carcinoma trial failures, accounting for 29.5% and 26.0% of ...